Intensity Therapeutics shares rise 10.58% premarket after Nasdaq grants 180-day extension to meet $1.00 bid price requirement.

Intensity Therapeutics (INTS) surged 10.58% in premarket trading following the announcement that Nasdaq granted the company a 180-day extension to regain compliance with the $1.00 minimum bid price requirement. This extension, extending the deadline to June 1, 2026, provides additional time for the stock to stabilize above the threshold, reducing the immediate risk of delisting and signaling regulatory flexibility. The move aligns with the company’s ongoing clinical trials for its lead candidate, INT230-6, and recent capital-raising efforts, which collectively underscore continued operational momentum despite the stock’s significant year-to-date decline. The news directly addresses investor concerns about liquidity and listing status, offering a near-term reprieve that likely spurred the premarket rally.